12/26
10:35 am
crmd
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? [Yahoo! Finance]
Low
Report
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? [Yahoo! Finance]
12/25
07:32 am
crmd
CorMedix (CRMD): Assessing Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
Medium
Report
CorMedix (CRMD): Assessing Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
12/19
02:44 pm
crmd
Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? [Yahoo! Finance]
Low
Report
Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? [Yahoo! Finance]
12/18
03:25 pm
crmd
CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
12/18
08:00 am
crmd
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
Medium
Report
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
12/16
09:02 am
crmd
5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]
Low
Report
5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]
11/24
07:25 pm
crmd
Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]
Medium
Report
Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]
11/20
08:10 pm
crmd
Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]
Low
Report
Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]
11/18
07:06 pm
crmd
Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025? [Yahoo! Finance]
Low
Report
Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025? [Yahoo! Finance]
11/18
06:38 am
crmd
Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]
Low
Report
Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]
11/18
05:22 am
crmd
H.C. Wainwright Raises the PT on ?CorMedix Inc. (CRMD), Keeps a Buy [Yahoo! Finance]
Low
Report
H.C. Wainwright Raises the PT on ?CorMedix Inc. (CRMD), Keeps a Buy [Yahoo! Finance]
11/14
02:57 pm
crmd
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating [Seeking Alpha]
Low
Report
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating [Seeking Alpha]
11/13
08:11 am
crmd
CorMedix (NASDAQ:CRMD) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
11/12
07:14 pm
crmd
Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline [Seeking Alpha]
Low
Report
Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline [Seeking Alpha]
11/12
02:21 pm
crmd
CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $16.00. They now have a "buy" rating on the stock.
11/12
02:21 pm
crmd
CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
11/12
11:13 am
crmd
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
11:13 am
crmd
CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentum [Seeking Alpha]
Medium
Report
CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentum [Seeking Alpha]
11/12
08:21 am
crmd
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance [Yahoo! Finance]
Medium
Report
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance [Yahoo! Finance]
11/12
07:34 am
crmd
CorMedix GAAP EPS of $1.26 beats by $0.63, revenue of $104.28M beats by $18.26M [Seeking Alpha]
Medium
Report
CorMedix GAAP EPS of $1.26 beats by $0.63, revenue of $104.28M beats by $18.26M [Seeking Alpha]
11/12
07:30 am
crmd
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
Low
Report
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
11/10
08:57 am
crmd
Assessing CorMedix (CRMD) Valuation After Recent Momentum Pause and Melinta Therapeutics Acquisition [Yahoo! Finance]
Low
Report
Assessing CorMedix (CRMD) Valuation After Recent Momentum Pause and Melinta Therapeutics Acquisition [Yahoo! Finance]
11/6
06:56 am
crmd
CorMedix (NASDAQ:CRMD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
CorMedix (NASDAQ:CRMD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/31
08:30 am
crmd
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
Medium
Report
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
10/25
11:32 pm
crmd
Assessing CorMedix (CRMD) Valuation Following Recent Share Price Fluctuations [Yahoo! Finance]
Low
Report
Assessing CorMedix (CRMD) Valuation Following Recent Share Price Fluctuations [Yahoo! Finance]